Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page

Stem cell mobilisation shows trend in improving major amputation rate in critical limb ischaemia patients

Monday, 20 Aug 2012 16:00
Eric T Choi
Eric T Choi

Results of a small randomised study presented at the Vascular Annual Meeting (Washington, DC, USA, June 2012) showed a trend toward improved major leg amputation-free survival with stem cell mobilisation therapy in patients with critical limb ischaemia. At 12 months, the major amputation rates were 50% for patients treated with mobilisation therapy and 83.3% in the control group (p=0.188).


Eric T Choi, associate professor of Surgery, chief, Section of Vascular Surgery, Temple University, Philadelphia, USA, told delegates that, in 1997, Jeffrey Isner’s lab in Boston discovered that a subset of bone-marrow-derived circulating cells was able to differentiate into endothelium and promote new blood vessel growth (Asahara et al. Science 1997; 275:964–7). He continued, “In 2006, Dan Link’s lab in St Louis showed that two types of such bone marrow-derived angiogenic cells are CD31, CD34, CD105 and CD144-positive endothelial progenitor cells (EPCs) and CD14, CD54-positive circulating angiogenic cells (CACS), as reported by Shepherd et al (Blood 2006; 108:3662–7).”

“Currently, there is no proven effective non-invasive treatment for critical limb ischaemia. We hypothesised that mobilisation of circulating angiogenic cells into the blood by subcutaneous injections of G-CSF may stimulate angiogenesis and result in a sustained improvement in blood flow in the lower extremities of patients with critical limb ischaemia,” Choi said.

Granulocyte colony-stimulating factor (G-CSF) is a drug that releases stem cells from the bone marrow into the blood.

The population at highest risk for impending leg amputation was identified as critical limb ischaemia patients (Rutherford category 5 or 6) with no surgical or endovascular revascularisation options, Choi said. After informed consent, patients were randomised (1:1) in a double-blinded fashion to treatment with daily subcutaneous injection of G-CSF (10μg/kg/day) or placebo for 10 days. Treatment failure was defined as an endpoint of major leg amputation at 12 months.

The investigatorsin the STEMPAD (Stem cell mobilisation to treat severe peripheral artery disease) studyenrolled 28 critical limb ischaemia patients; of which 24 have completed the 12-month follow-up (four patients did not finish the 10-day course of G-CSF or placebo). There were no significant differences between treatment and control groups in any of the demographic parameters.

At 12 months, the major amputation rates were 50% (six out of 12) for G-CSF group and 83.3% (10 out of 12) for control group (log-rank test, p=0.188). Choi said, “However, after four months, none of six remaining G-CSF treated subjects required a major amputation while three out of five remaining controlled subjects went on to have a major amputation suggesting that minimal effective duration of therapeutic angiogenesis from G-CSF treatment is four months. No adverse effects attributable to subcutaneous injection of G-CSF were reported.”

Choi stated that G-CSF is well tolerated in critical limb ischaemia patients and that 10μg/kg/day can mobilise EPCs and CACs effectively in these patients.

“We performed the first randomised, placebo-controlled, double-blinded study of C-GSF-induced angiogenic cell mobilisation to treat no-option critical limb ischaemia patients in the USA. This analysis was designed to demonstrate feasibility and safety of G-CSF treatment, and the preliminary data support a larger clinical trial to determine the effectiveness of G-CSF in critical limb ischaemia patients,” Choi said.

Add New Comment

Related Items

Most popular

Incraft low-profile endograft launched in Europe and Canada
Wednesday, 10 Sep 2014
Cordis announced on 10 September the launch of its Incraft AAA Stent Graft System, an ultra-low profile device for use during endovascular aneurysm repair (EVAR) for patients suffering from ... Incraft low-profile endograft launched in Europe and Canada

First patient enrolled in US study of Novate’s Sentry IVC filter
Monday, 22 Sep 2014
Novate Medical has announced that Souheil Saddekni, professor of Vascular and Interventional Radiology at the University of Alabama, Birmingham, USA, has enrolled the first patient in the SENTRY IDE ... First patient enrolled in US study of Novate’s Sentry IVC filter

First drug-eluting balloon approved in USA
Friday, 10 Oct 2014
The FDA has approved the Lutonix drug-eluting balloon for the management of peripheral artery disease. This is the first time that the agency has approved such a device for this indication in the USA. First drug-eluting balloon approved in USA


Not all drug-eluting balloons are equal
Wednesday, 15 Oct 2014
Thomas Zeller, Bad Krozingen, Germany, analyses the results of two recent randomised controlled trials comparing drug-eluting balloons to angioplasty alone in femoropopliteal lesions. Not all drug-eluting balloons are equal

Renal stenting may benefit patients excluded from randomised trials, says expert consensus
Wednesday, 15 Oct 2014
Sahil A Parikh, Case Western Reserve University School of Medicine, Cleveland, USA, speaks to Vascular News about the Society for Cardiovascular Angiography and Interventions expert consensus on ... Renal stenting may benefit patients excluded from randomised trials, says expert consensus


Martin Björck
Wednesday, 01 Oct 2014
Martin Björck, Uppsala University Hospital, Sweden, holds the only professor-chair of vascular ... Martin Björck

Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions